Cargando…

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression

The authors showed a mechanism for attenuating atherosclerosis by directly administering an oral factor Xa inhibitor (ie, rivaroxaban [RIV]). The autophagy activity of macrophages was significantly suppressed by factor Xa and was alleviated by the administration of RIV. However, factor Xa failed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Yusuke, Maejima, Yasuhiro, Nakagama, Shun, Shiheido-Watanabe, Yuka, Tamura, Natsuko, Sasano, Tetsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Preclinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733676/ https://www.ncbi.nlm.nih.gov/pubmed/35024502 http://dx.doi.org/10.1016/j.jacbts.2021.09.010

Ejemplares similares

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis
por: Shiheido-Watanabe, Yuka, et al.
Publicado: (2021)

Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity
por: Nakagama, Shun, et al.
Publicado: (2023)

Neutrophil extracellular traps-mediated Beclin-1 suppression aggravates atherosclerosis by inhibiting macrophage autophagy
por: Sano, Masataka, et al.
Publicado: (2022)

Plasma apolipopotein C-2 elevation is associated with Takayasu arteritis
por: Tamura, Natsuko, et al.
Publicado: (2021)

Porphyromonas gingivalis, a periodontal pathogen, impairs post-infarcted myocardium by inhibiting autophagosome–lysosome fusion
por: Shiheido-Watanabe, Yuka, et al.
Publicado: (2023)

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
por: Sohma, Ryoichi, et al.
Publicado: (2023)

The Pathophysiological Significance of “Mitochondrial Ejection” from Cells
por: Fan, Qintao, et al.
Publicado: (2022)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose
por: Carr, Brendan M., et al.
Publicado: (2018)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
por: Harenberg, Job, et al.
Publicado: (2011)

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
por: Horinaka, Shigeo, et al.
Publicado: (2017)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Roles of factor Xa beyond coagulation
por: Ruf, Wolfram
Publicado: (2021)

Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme
por: Haas, Sylvia
Publicado: (2009)

Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice
por: Wu, Tao-Cheng, et al.
Publicado: (2015)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
por: Remko, Milan, et al.
Publicado: (2016)

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
por: Perzborn, E, et al.
Publicado: (2014)

The Role of Anti-Factor Xa Activity in the Management of Ecchymosis in Patients Receiving Rivaroxaban after Total Knee Arthroplasty
por: Wang, Han, et al.
Publicado: (2023)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways
por: Zhang, Qian, et al.
Publicado: (2023)

Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis
por: Moran, Corey S., et al.
Publicado: (2017)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition
por: Meah, Mohammed N., et al.
Publicado: (2020)

Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry
por: Hamada, Satomi, et al.
Publicado: (2018)

The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin
por: Solayar, Gandhi N, et al.
Publicado: (2011)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice
por: Posthuma, Jelle J., et al.
Publicado: (2019)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

An experiment with VM/XA share
por: Pope, B G
Publicado: (1990)

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

Author Correction: Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry
por: Hamada, Satomi, et al.
Publicado: (2019)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation
por: Lucas, Fabienne, et al.
Publicado: (2021)

Marker-aided Incorporation of Xa38, a Novel Bacterial Blight Resistance Gene, in PB1121 and Comparison of its Resistance Spectrum with xa13 + Xa21
por: Ellur, Ranjith K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_id3vk7ntuul5okutuh82hs7de5